Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

被引：0
|
作者：
McGuire, D. K. [1 ]
Cannon, C. P. [2 ]
Pratley, R. [3 ]
Dagogo-Jack, S. [4 ]
Mancuso, J. [5 ]
Huyck, S. [6 ]
Charbonnel, B. [7 ]
Shih, W. J. [8 ]
Gallo, S. [9 ]
Masiukiewicz, U. [5 ]
Golm, G. [6 ]
Cosentino, F. [10 ]
Lauring, B. [6 ]
Terra, S. G. [11 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Harvard Med Sch, Baim Inst Clin Res, Boston, MA USA
[3] Florida Hosp, Translat Res Inst Metab & Diabet, Orlando, FL USA
[4] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Merck & Co Inc, Kenilworth, NJ USA
[7] Univ Nantes, Nantes, France
[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[9] Pfizer Inc, Berlin, Germany
[10] Karolinska Univ Hosp Solna, Unit Cardiol, Stockholm, Sweden
[11] Pfizer Inc, Andover, MA USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
629
引用
收藏
页码：S305 / S306
页数：2
相关论文
共 50 条
  • [1] Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
    Cannon, Christopher P.
    Mcguire, Darren K.
    Pratley, Richard
    Dagogo-Jack, Sam
    Mancuso, James
    Huyck, Susan
    Charbonnel, Bernard
    Shih, Weichung J.
    Gallo, Silvina
    Masiukiewicz, Urszula
    Golm, Gregory
    Cosentino, Francesco
    Lauring, Brett
    Terra, Steven G.
    [J]. AMERICAN HEART JOURNAL, 2018, 206 : 11 - 23
  • [2] DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
    Cannon, Christopher P.
    McGuire, Darren
    Pratley, Richard
    Dagogo-Jack, Samuel
    Mancuso, James
    Huyck, Susan
    Charbonnel, Bernard
    Shih, Weichung
    Gallo, Silvina
    Masiukiewicz, Urszula
    Golm, Gregory
    Francesco, Cosentino
    Lauring, Brett
    Terra, Steven
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1825 - 1825
  • [3] Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart, Kevin
    Carris, Nicholas W.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (02) : 163 - 165
  • [4] Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial
    Cherney, David Z. I.
    Cosentino, Francesco
    McGuire, Darren K.
    Kolkailah, Ahmed A.
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Frederich, Robert
    Maldonado, Mario
    Liu, Chih-Chin
    Cannon, Christopher P.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 746 - 753
  • [5] Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
    Cosentino, Francesco
    Cannon, Christopher P.
    Frederich, Robert
    Cherney, David Z. I.
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Mancuso, James P.
    Maldonado, Mario
    Cater, Nilo B.
    Wang, Shuai
    McGuire, Darren K.
    [J]. CIRCULATION, 2022, 146 (08) : 652 - 654
  • [6] Cardiorenal outcomes with ertugliflozin by baseline cardiorenal medications: an analysis from VERTIS CV
    Cannon, C. P.
    Cosentino, F.
    McGuire, D. K.
    Charbonnel, B.
    Dagogo-Jack, S.
    Pratley, R. E.
    Shih, W. J.
    Maldonado, M.
    Pong, A.
    Gantz, I.
    Frederich, R.
    Mancuso, J. P.
    Masiukiewicz, U.
    Cherney, D. Z. I.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 29 - 30
  • [7] Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Charbonnel, Bernard
    Dagogo-Jack, Samuel
    Pratley, Richard E.
    Shih, Weichung J.
    Maldonado, Mario
    Pong, Annpey
    Gantz, Ira
    Frederich, Robert
    Mancuso, James P.
    Masiukiewicz, Urszula
    Cannon, Christopher P.
    [J]. DIABETES, 2021, 70
  • [8] Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial
    Cosentino, F.
    Cannon, C. P.
    Cherney, D. Z. I.
    Dagogo-Jack, S.
    Pratley, R. E.
    Charbonnel, B.
    Shih, W. J.
    Mancuso, J. P.
    Maldonado, M.
    Frederich, R.
    Cater, N. B.
    Wang, S.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2650 - 2650
  • [9] Cardiorenal outcomes with ertugliflozin by baseline glucose-lowering agent: an analysis from VERTIS CV
    Charbonnel, B.
    Dagogo-Jack, S.
    Cannon, C. P.
    Cherney, D. Z. I.
    Cosentino, F.
    McGuire, D. K.
    Shih, W. J.
    Liu, J.
    Pong, A.
    Gantz, I.
    Frederich, R.
    Mancuso, J. P.
    Pratley, R. E.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 226 - 226
  • [10] Should Cardiologists Risk-stratify Patients With Atherosclerotic Cardiovascular Disease by Kidney Function? Results From the VERTIS CV Trial Evaluating Efficacy of Ertugliflozin on Cardiovascular and Kidney Outcomes by Baseline Kidney Function
    Cherney, David
    Charbonnel, Bernard
    Cosentino, Francesco
    Pratley, Richard
    Dagogo-Jack, Samuel
    Shih, Weichung J.
    McGuire, Darren K.
    Frederich, Robert
    Maldonado, Mario
    Liu, Jie
    Pong, Annpey
    Liu, Chih-Chin
    Cannon, Christopher P.
    [J]. CIRCULATION, 2020, 142 (24) : E483 - E483
12345